StockNow
CalendarLog in
U.S. Markets

Eli Lilly (LLY) says it will present new data on Foundayo, retatrutide and eloraTZP at EASD 2026; delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes

StockNow breaking-news AI analysis

Eli Lilly will present positive weight-loss and A1C data for Foundayo, retatrutide, and eloraTZP at EASD 2026, strengthening its metabolic pipeline ahead of retatrutide's planned Q1 2027 regulatory filing.

1 stocks
LLYEli Lilly & Co.$1,156.10Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Iranian government aircraft that departed Tehran is reportedly preparing to land in Saudi Arabia, raising speculation that an Iranian delegation may be heading to Riyadh amid escalating Saudi-Houthi tensions, Kann News reporter says

Geopolitics

Iran Government plane lands in Riyadh, Saudi Arabia, according to live tracking data

Other

MediaTek (2454 TT) launches Dimensity 9600 Pro, its first mobile chip built on TSMC's (TSM) 2nm process

TSM